Nasdaq

Disc presents clinical, translational data across portfolio at ASH meeting

DISC-0974: DISC-0974+Ruxolitinib Mouse Model: Wild-type mice were randomized to receive doses of placebo, ruxolitinib, DBIO-100, or a combination of ruxolitinib and DBIO-100. Results showed: ...
Yahoo Finance

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Nasdaq

Disc Medicine, Inc. to Present Key Data from Hematology Portfolio at EHA 2025 Congress

Disc Medicine, Inc. announced it will present data from its hematology portfolio at the European Hematology Association (EHA) 2025 Congress in Milan from June 12-15, 2025. The presentations will ...
Seeking Alpha

Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript

Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, John Quisel, CEO. Please go ahead. Good morning, and welcome to the ...